According to the results of a new clinical trial published in The New England Journal of Medicine (NEJM), a simple treatment that combines four heart medicines in one pill—a “polypill”—was able to cut the risk of heart attack, stroke, and other cardiovascular events by 21% in people at risk of heart disease, and by 31% […]
In this editorial from The New England Journal of Medicine, the authors criticize the country’s leadership on its response to the COVID-19 pandemic, presenting several pieces of evidence to reinforce their claims. From politicizing the Food and Drug Administration (FDA) to undercutting trust in science and government, the leaders of our nation are “causing damage […]
Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.
NEJM explores the question: Are we, in fact, what we eat? Can the periodic flipping of a “metabolic switch” truly help patients?